235 related articles for article (PubMed ID: 37148882)
1. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W; Gall-Mas L; Falco MM; Li Y; Lavikka K; Kriegbaum MC; Oikkonen J; Bulanova D; Pietras EJ; Voßgröne K; Chen YJ; Erkan EP; Dai J; Lundgren A; Grønning Høg MK; Larsen IM; Lamminen T; Kaipio K; Huvila J; Virtanen A; Engelholm L; Christiansen P; Santoni-Rugiu E; Huhtinen K; Carpén O; Hynninen J; Hautaniemi S; Vähärautio A; Wennerberg K
Dev Cell; 2023 Jun; 58(12):1106-1121.e7. PubMed ID: 37148882
[TBL] [Abstract][Full Text] [Related]
2. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
3. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
[TBL] [Abstract][Full Text] [Related]
4. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Hill SJ; Decker B; Roberts EA; Horowitz NS; Muto MG; Worley MJ; Feltmate CM; Nucci MR; Swisher EM; Nguyen H; Yang C; Morizane R; Kochupurakkal BS; Do KT; Konstantinopoulos PA; Liu JF; Bonventre JV; Matulonis UA; Shapiro GI; Berkowitz RS; Crum CP; D'Andrea AD
Cancer Discov; 2018 Nov; 8(11):1404-1421. PubMed ID: 30213835
[TBL] [Abstract][Full Text] [Related]
5. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
6. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S; Iyer S; Ran H; Dolgalev I; Gu S; Wei W; Foster CJR; Loomis CA; Olvera N; Dao F; Levine DA; Weinberg RA; Neel BG
Cancer Discov; 2021 Feb; 11(2):362-383. PubMed ID: 33158842
[TBL] [Abstract][Full Text] [Related]
7. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
[TBL] [Abstract][Full Text] [Related]
8. An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
Chen YA; Lu CY; Cheng WF; Kuo KT; Yu CW; Ho HN; Chen HF; Pan SH
BMC Cancer; 2022 Sep; 22(1):967. PubMed ID: 36085021
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
Kumar S; Raina M; Tankay K; Ingle GM
Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
[TBL] [Abstract][Full Text] [Related]
11. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
[TBL] [Abstract][Full Text] [Related]
12. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
[TBL] [Abstract][Full Text] [Related]
14. Protocol for establishing organoids from human ovarian cancer biopsies.
Maenhoudt N; Vankelecom H
STAR Protoc; 2021 Jun; 2(2):100429. PubMed ID: 33870230
[TBL] [Abstract][Full Text] [Related]
15. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.
Hoffmann K; Berger H; Kulbe H; Thillainadarasan S; Mollenkopf HJ; Zemojtel T; Taube E; Darb-Esfahani S; Mangler M; Sehouli J; Chekerov R; Braicu EI; Meyer TF; Kessler M
EMBO J; 2020 Mar; 39(6):e104013. PubMed ID: 32009247
[TBL] [Abstract][Full Text] [Related]
16. Organoid of ovarian cancer: genomic analysis and drug screening.
Liu HD; Xia BR; Jin MZ; Lou G
Clin Transl Oncol; 2020 Aug; 22(8):1240-1251. PubMed ID: 31939100
[TBL] [Abstract][Full Text] [Related]
17. Integration of Genomic Profiling and Organoid Development in Precision Oncology.
Yoon H; Lee S
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008642
[TBL] [Abstract][Full Text] [Related]
18. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
19. Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
Feng L; Yang W; Zhao H; Bakkum-Gamez J; Sherman ME; Kannan N
Methods Mol Biol; 2022; 2429():445-454. PubMed ID: 35507180
[TBL] [Abstract][Full Text] [Related]
20. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
